Medical Disclaimer: Probiotics are generally safe. Immunocompromised individuals (central lines, ICU, HIV/CD4<200, immunosuppressants) should avoid — risk of bacteremia/fungemia. Consult a healthcare provider if you have short bowel syndrome, cardiac valve disease, or are on immunosuppressants.
Key Takeaways
- Strain specificity is everything. Lactobacillus rhamnosus GG ≠Lactobacillus rhamnosus GR-1. Effects are strain-specific, not species-specific.
- CFU at expiration > CFU at manufacture. Probiotics die over time. Demand “guaranteed at expiration” or third-party verification.
- Survivability matters. Stomach acid (pH 1.5–3.5) kills most. Look for: enteric coating, spore form (Bacillus), or proven acid/bile tolerance.
- Condition-specific strains work; general multis don’t. Match strain to condition (AAD → S. boulardii + L. rhamnosus GG; IBS bloating → B. longum 35624; vaginal health → L. rhamnosus GR-1 + L. reuteri RC-14).
- More strains ≠better. 10 strains at 1B each ≠1 strain at 10B with evidence. Ecological competition may reduce efficacy.
Probiotic Strains by Condition (Evidence-Graded)
| Condition | Strain (Specific) | Dose | Grade | Key Evidence |
|---|---|---|---|---|
| Antibiotic-Associated Diarrhea (AAD) | Saccharomyces boulardii CNCM I-745 | 250–500mg 2x/day | A | Cochrane: ↓ AAD 50–60%, ↓ C. diff 60% |
| Lactobacillus rhamnosus GG (ATCC 53103) | 10–20B CFU/day | A | Meta-analysis: ↓ AAD 50% (pediatric strongest) | |
| C. difficile Prevention | S. boulardii CNCM I-745 + L. rhamnosus GG | 500mg 2x/d + 20B CFU/d | A | NNT = 29 for C. diff prevention |
| IBS (Bloating/Pain) | Bifidobacterium longum 35624 (Align®) | 1B CFU/day | B | RCTs: ↓ bloating, ↓ abdominal pain vs placebo |
| Lactobacillus plantarum 299v | 10B CFU/day | B | RCTs: ↓ abdominal pain, ↑ stool frequency | |
| Acute Infectious Diarrhea | L. rhamnosus GG + S. boulardii | 10B CFU + 500mg 2x/d | A | Cochrane: ↓ duration ~1 day |
| Traveler’s Diarrhea | S. boulardii CNCM I-745 | 250mg 2x/d (start 5d before) | B | RCTs: ↓ incidence 15–20% |
| H. pylori Eradication Adjunct | S. boulardii CNCM I-745 | 500mg 2x/d × 14d | A | ↑ Eradication rate, ↓ side effects |
| Lactobacillus reuteri DSM 17648 (Pylopass®) | 10^8 CFU/day | B | Binds H. pylori in stomach | |
| Vaginal Health (BV, Yeast, UTI) | L. rhamnosus GR-1 + L. reuteri RC-14 | 1–5B CFU/day (oral or vaginal) | A | RCTs: ↓ BV recurrence, ↓ UTI recurrence |
| Atopic Dermatitis Prevention (Infant) | L. rhamnosus GG (maternal + infant) | 10B CFU/day (last trimester + 6mo) | B | ↓ incidence 50% in high-risk |
| Ulcerative Colitis (Pouchitis) | VSL#3 / Visbiome® (8 strains, 450–900B) | 450–900B CFU/day | A | Maintains remission; pouchitis prevention |
| Hepatic Encephalopathy | VSL#3 / Visbiome® | 900B CFU/day | A | ↓ episodes, ↓ hospitalization |
What Makes a Quality Probiotic?
| Criterion | Why It Matters | How to Verify |
|---|---|---|
| Strain-Level ID | Species-level (e.g., “L. acidophilus”) is meaningless; need strain (e.g., “L. acidophilus NCFM”) | Label lists genus, species, strain designation (ATCC, DSM, proprietary) |
| CFU at Expiration | Probiotics die; “at manufacture” is marketing. Guaranteed at expiry = real dose. | Label: “Guaranteed 10B CFU at expiration” + lot number + expiry date |
| Survivability Data | Stomach acid (pH 1.5–3.5) kills 90–99% of non-protected strains. | Published gastric/bile tolerance studies; enteric coating; spore form (Bacillus) |
| Third-Party Testing | Identity, potency, contaminants (heavy metals, allergens, gluten). | NSF, USP, ConsumerLab, Informed Choice seals + lot-specific CoA on website |
| No Proprietary Blends | Each strain + CFU disclosed. “10 strains 50B CFU” = pixie dusting if not disclosed. | Label lists each strain + individual CFU |
| Appropriate Prebiotic | Inulin/FOS can cause gas. PHGG or resistant starch better tolerated. | If included: PHGG, acacia, resistant starch — not inulin/FOS as primary |
Top Tested Brands by Category (2024)
AAD / C. diff / Travel / H. pylori — S. boulardii + L. rhamnosus GG
| Brand | Product | Strains + CFU | Testing | Cost/Day |
|---|---|---|---|---|
| Florastor® | Daily Probiotic | S. boulardii CNCM I-745 250mg (5B CFU) | Third-party, CoA | $0.60 |
| Jarrow Formulas | Saccharomyces Boulardii + MOS | S. boulardii 5B CFU + MOS 150mg | ConsumerLab, CoA | $0.35 |
| Culturelle® | Digestive Daily | L. rhamnosus GG 10B CFU | NSF, ConsumerLab | $0.45 |
| Thorne | Saccharomyces Boulardii | S. boulardii 5B CFU | NSF Sport, TGA | $0.50 |
| Pure Encapsulations | Saccharomyces Boulardii | S. boulardii 5B CFU | NSF, USP | $0.55 |
IBS Bloating — B. longum 35624 (Align® Strain)
| Brand | Product | Strain + CFU | Testing | Cost/Day |
|---|---|---|---|---|
| Align® | Probiotic | B. longum 35624 1B CFU | ConsumerLab, CoA | $0.70 |
| Garden of Life | Dr. Formulated Once Daily | B. longum 35624 (in blend) 50B CFU | NSF, ConsumerLab | $0.80 |
General Gut Health / Maintenance — Multi-Strain (Evidence-Based Formulations)
| Brand | Product | Key Strains + CFU | Testing | Cost/Day |
|---|---|---|---|---|
| VSL#3 / Visbiome® | High Potency | 8 strains, 450B (VSL#3) / 900B (Visbiome) — L. casei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. breve, B. infantis, S. thermophilus | Third-party, CoA | $3.00–5.00 |
| Seed | DS-01 Daily Synbiotic | 24 strains, 53B AFU (viable cells) — L. plantarum, B. longum, L. rhamnosus, etc. | ConsumerLab, CoA | $1.50 |
| Ritual | Synbiotic+ | 11 strains, 11B CFU — L. rhamnosus GG, B. lactis BB-12, etc. + prebiotic (PHGG) | USP, ConsumerLab | $1.00 |
| Thorne | FloraMend Prime Probiotic | 3 strains, 5B CFU — L. gasseri KS-13, B. longum MM-2, B. bifidum G9-1 | NSF Sport, TGA | $1.20 |
Vaginal Health — L. rhamnosus GR-1 + L. reuteri RC-14
| Brand | Product | Strains + CFU | Delivery | Cost/Day |
|---|---|---|---|---|
| Jarrow Formulas | Fem-Dophilus | L. rhamnosus GR-1 + L. reuteri RC-14, 5B CFU | Oral capsule | $0.40 |
| RepHresh | Pro-B Probiotic | L. rhamnosus GR-1 + L. reuteri RC-14, 5B CFU | Oral capsule | $0.50 |
| Metagenics | UltraFlora Women’s | L. rhamnosus GR-1 + L. reuteri RC-14, 10B CFU | Oral capsule | $0.60 |
Budget Value — Tested, Strain-Disclosed
| Brand | Product | Key Strains + CFU | Testing | Cost/Day |
|---|---|---|---|---|
| NOW Foods | Probiotic-10 | 10 strains, 25B CFU (L. acidophilus, B. lactis, L. plantarum, L. rhamnosus, etc.) | ConsumerLab, CoA | $0.20 |
| Nutricost | Probiotic Complex | 10 strains, 30B CFU | ConsumerLab | $0.15 |
| Kirkland (Costco) | Probiotic | 10 strains, 20B CFU | ConsumerLab | $0.08 |
Probiotic Myths Debunked
| Myth | Reality |
|---|---|
| “More strains = better” | Ecological competition; 1 evidence-based strain > 10 unproven. Multis often underdose each strain. |
| “Higher CFU = better” | Dose-response plateaus; 1–10B evidence-based for most strains. 100B of unproven strains = expensive urine. |
| “Refrigerated = better” | Some strains shelf-stable (spore, lyophilized). Refrigerated ≠quality; stability data matters. |
| “Take on empty stomach” | Food buffers acid; improves survival for most strains. Take with meal or 30 min before. |
| “Rotate probiotics monthly” | No evidence. Consistency allows colonization/adaptation. Rotate only if switching indication. |
| “Probiotics colonize permanently” | Most are transient (days–weeks). Benefits from metabolic activity, not permanent residency. |
| “Soil-based / spore probiotics are superior” | Bacillus spores survive well but less human outcome data vs Lacto/Bifido. Safety concerns (bacteremia in immunocompromised). |
| “Everyone needs a daily probiotic” | Healthy adults: no RCT evidence for daily multi-strain. Food-first (fermented + fiber) builds resilient ecosystem. |
Probiotic Decision Matrix
| Your Situation | Probiotic Strategy | Skip |
|---|---|---|
| Starting antibiotics | S. boulardii 500mg 2x/d + L. rhamnosus GG 20B/d (Day 1 – 7d post) | Random multi-strain |
| IBS bloating/pain | B. longum 35624 (Align) 1B/d or L. plantarum 299v 10B/d | Random multi-strain, high-FODMAP prebiotics |
| Traveler’s diarrhea prevention | S. boulardii 250mg 2x/d (start 5d before) | Random multi-strain |
| Recurrent BV / UTI / yeast | L. rhamnosus GR-1 + L. reuteri RC-14 5B/d (oral) | Random Lactobacillus blends |
| Post-antibiotic recovery | S. boulardii + L. rhamnosus GG 2 weeks post; fermented foods 2x/d | “Gut repair” blends |
| Pregnancy (allergy prevention) | L. rhamnosus GG 10B/d (3rd trimester + infant 6mo) | Random prenatal probiotics |
| Healthy adult, no issues | Food-first: fermented foods 1–2x/d + 30 plants/week fiber | Daily multi-strain probiotic |
| Immunocompromised | AVOID — bacteremia/fungemia risk | All live probiotics |
Frequently Asked Questions
Should I take probiotics with antibiotics?
Yes. Start Day 1 of antibiotics. Separate by 2–3 hours (antibiotic kills probiotic). Continue 7–14 days AFTER antibiotic course. S. boulardii (yeast) survives antibiotics; L. rhamnosus GG (bacteria) needs separation.
Do probiotics need to be refrigerated?
Not necessarily. Shelf-stable technology (lyophilization, microencapsulation, spore forms) provides stability. Check label: if “refrigerate after opening” → refrigerate. If “shelf-stable” + stability data → room temp OK. Refrigeration extends life but isn’t a quality marker alone.
Can probiotics cause SIBO?
Rare. Case reports of D-lactic acidosis / bacteremia in short bowel, immunocompromised. In healthy: no evidence probiotics cause SIBO. If bloating worsens: stop, assess for SIBO, consider PHGG instead.
What about spore probiotics (Bacillus subtilis, Bacillus coagulans)?
Survive stomach acid well (spore form). Some RCTs for IBS, AAD. BUT: limited long-term safety data; theoretical risk of horizontal gene transfer; bacteremia reports in immunocompromised. Lacto/Bifido have 30+ years safety data. Use spores only if specific indication + MD guidance.
References
- Hempel S, et al. “Probiotics for AAD.” JAMA. 2012;307(18):1959-1969.
- Goldenberg JZ, et al. “Probiotics for C. diff Prevention.” Cochrane. 2017;12:CD006095.
- Ford AC, et al. “Efficacy of Probiotics in IBS.” Am J Gastroenterol. 2018;113(7):1011-1022.
- Reid G, et al. “Probiotics for Vaginal Health.” Nat Rev Urol. 2019;16(11):621-634.
- Szajewska H, et al. “Lactobacillus rhamnosus GG for AAD.” Aliment Pharmacol Ther. 2015;42(10):1149-1157.
- McFarland LV. “Meta-analysis of Probiotics for AAD.” Travel Med Infect Dis. 2015;13(1):42-52.
